Literature DB >> 30737128

Unawareness of HCV serostatus among persons newly diagnosed with HIV.

Paola Scognamiglio1, Assunta Navarra2, Nicoletta Orchi1, Gabriella De Carli1, Silvia Pittalis3, Ilaria Mastrorosa4, Ubaldo Visco Comandini5, Chiara Agrati6, Andrea Antinori4, Vincenzo Puro1, Giuseppe Ippolito7, Enrico Girardi3.   

Abstract

Treatment of chronic HCV infection with direct acting antivirals can achieve high rates of sustained viral response in persons with HIV. In the perspective of HCV elimination in this population, high rates of HCV detection will be needed. We evaluated the unawareness of HCV infection in 2927 persons newly diagnosed with HIV during 2004-2015 in Rome, Italy. Two-hundred-fifty persons (8.5%) were anti-HCV positive. The proportion of HCV-unaware individuals at the time of HIV diagnosis was 58.0% (145/250), without significant variations over time, 17.2% showed an advanced fibrosis stage. The absence of previous HIV testing was significantly associated with HCV unawareness.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  HCV; HIV-HCV coinfection; Hepatitis; Italy; Late diagnosis

Mesh:

Year:  2019        PMID: 30737128     DOI: 10.1016/j.jiph.2019.01.055

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  2 in total

1.  Epidemiological risk factors associated with primary infection by Epstein-Barr virus in HIV-1-positive subjects in the Brazilian Amazon region.

Authors:  Leonn Mendes Soares Pereira; Eliane Dos Santos França; Iran Barros Costa; Igor Tenório Lima; Amaury Bentes Cunha Freire; Francisco Lúzio de Paula Ramos; Talita Antonia Furtado Monteiro; Olinda Macedo; Rita Catarina Medeiros Sousa; Felipe Bonfim Freitas; Igor Brasil Costa; Antonio Carlos Rosário Vallinoto
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.996

2.  HIV and the liver.

Authors:  Kenneth E Sherman; Marion G Peters; David L Thomas
Journal:  Top Antivir Med       Date:  2019-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.